Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00968851 · ClinicalTrials.gov registry record · Phase 2
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Phase 2 study of Schizophrenia and Cognition, sponsored by FORUM Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 317
- Enrollment target
- 20
- Study locations
NCT00968851: Completed Phase 2 study of Schizophrenia and Cognition, sponsored by FORUM Pharmaceuticals.
NCT00968851 is a Phase 2 study of Schizophrenia and Cognition that has completed, run by FORUM Pharmaceuticals. The registered enrollment target is 317 participants, above the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target (45% higher). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00968851, a Phase 2 study of Schizophrenia and Cognition, has completed, sponsored by FORUM Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 317 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is being conducted to determine the safety and effect on cognitive function of two different doses of an investigational medication, EVP-6124, in individuals with schizophrenia who are on chronic stable atypical anti-psychotic therapy. In addition, behavioral and psychotic symptoms will be evaluated.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG EVP-6124
Study Locations (20)
Other
- - Arkhangelsk
- - Kazan'
- - Moscow
- - Moscow
- - Saint Petersburg
- - Stavropol
California
- Intergrated Medical and Behavioral Associates - Glendale
- Excell Research - Oceanside
- University of California, San Diego - San Diego
- Affiliated Research Institute - San Diego
- Schuster Medical Research Institute - Sherman Oaks
Illinois
- Uptown Research Institute - Chicago
- Alexian Brothers Behavioral Health - Hoffman Estates
Texas
- FutureSearch Clinical Trials, L.P. - Austin
- InSite Clinical Research - DeSoto
Florida
- Scientific Clinical Research, Inc. - North Miami
Maryland
- CBH Health, LLC - Rockville
New Jersey
- CRI Worldwide - Willingboro
South Carolina
- Carolina Clinical Trials, Inc. - Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 317 participants |
| Start Date | 2009-12 |
| Est. Completion | 2011-03 |
| Phase | Phase 2 |
What the finished NCT00968851 record still lists
NCT00968851 is an interventional study that assigns participants to a tested intervention. The registered 317 participants enrollment target is mid-sized for trials with a published cap, above the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target (45% higher).
The record links to 3 conditions, with Schizophrenia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00968851 names 20 study sites across 9 states, led by Other, California, Illinois.
Frequently Asked Questions
What is clinical trial NCT00968851 about?
NCT00968851 is a clinical study titled "Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia". This study is being conducted to determine the safety and effect on cognitive function of two different doses of an investigational medication, EVP-6124, in individuals with schizophrenia who are on chronic stable atypical anti-psychotic therapy. In addition, behavioral and psychotic symptoms will b...
What is the current status of trial NCT00968851?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 317 participants. The study started on 2009-12. Estimated completion is 2011-03.
What conditions does trial NCT00968851 study?
This clinical trial studies the following conditions: Schizophrenia, Cognition, Central Nervous System Diseases.
What interventions are being tested in trial NCT00968851?
The interventions under investigation include: Placebo (DRUG), EVP-6124 (DRUG).
Who is sponsoring clinical trial NCT00968851?
This trial is sponsored by FORUM Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00968851 being conducted?
This trial has 20 study locations across California, Florida, Illinois, Maryland, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00968851's enrollment target sits among peer trials
317 55th of 315 higher than 261 of 315 other Schizophrenia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia
RECRUITING · Phase 2
-
Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia
RECRUITING · Phase 2
-
A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia
RECRUITING · Phase 2
-
Low-dose Buprenorphine as a Modulator of Social Motivation in Schizophrenia
RECRUITING · Phase 2
-
Study of ALTO-101 in Patients With Schizophrenia
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04594642 · 317 participants · Phase 1
A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma
- NCT04977453 · 317 participants · Phase 1
GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
- NCT05137054 · 317 participants · Phase 1
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
- NCT05382754 · 317 participants · NA
Home Apnea Testing in CHildren Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia